Tag: CYP2C9
Warfarin Genetics: How CYP2C9 and VKORC1 Variants Affect Bleeding Risk and Dosing
Warfarin genetics, driven by CYP2C9 and VKORC1 variants, significantly impact bleeding risk and dosing accuracy. Genetic testing can reduce dangerous INR spikes and major bleeding by up to 32% in the first 90 days of therapy.